Replies to post #172421 on Biotech Values

[mcbio]

Unfortunately, Peregrine is the one driving the Anti-Phosphatidylserine bus. However, I'm obviously intrigued by cellular mutations caused by pathogenic events, in this case, malignant neoplasm.

Over the past 20 years since Phosphatidylserine was found to have immune consequences, as a result of such cellular mutation, there have been no less than 2000 peer review articles written about PS. It's also well known, and un-debatable that PS, is cloaking, and that metastasis is a direct result of such masking..

With that said, the question that needs to be asked is; "how valuable is flipped PS to metastatic neoplasia survival"?

More than nothing, and less than everything?

John, if PS is so promising a target and bavituximab hits it, then why hasn't there been any compelling clinical data to date? I really do think it's as simple as that.

[DewDiligence]

PPHM selling an unspecified amount of convertible preferred stock:

http://finance.yahoo.com/news/peregrine-pharmaceuticals-announces-public-offering-210100824.html